- Conditions
- Glioma, Astrocytoma, Oligodendroglioma, Ependymoma, Ganglioglioma, Pleomorphic Xanthoastrocytoma
- Interventions
- Part 1 Survey Group, Part 2 Focus Group
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 1,308
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Astrocytoma, Glioblastoma
- Interventions
- CC-90010
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Boston, Massachusetts
- Conditions
- Glioblastoma
- Interventions
- Optune
- Device
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Temple, Texas
- Conditions
- Patients With Newly Diagnosed Glioblastoma
- Interventions
- PLX3397, Radiation Therapy, Temozolomide
- Drug · Radiation
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Detroit, Michigan + 4 more
- Conditions
- Recurrent High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma
- Interventions
- PCI 24781, Temozolomide
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy (IMRT), Temozolomide, Chloroquine, Tumor Treating Fields Therapy (TTF)
- Radiation · Drug · Procedure
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Glioblastoma, Recurrent Brain Neoplasm
- Interventions
- Palliative Radiation Therapy, Questionnaire Administration, Radiation Therapy Treatment Planning and Simulation
- Radiation · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Brain Neoplasms
- Interventions
- Tumor fluorescence
- Drug
- Lead sponsor
- Southern Illinois University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 1
- States / cities
- Springfield, Illinois
- Conditions
- Glioblastoma
- Interventions
- G-202
- Drug
- Lead sponsor
- GenSpera, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma, Epithelial Ovarian Carcinoma, Mesothelioma, Gastroenteropancreatic Neuroendocrine Tumor, SCLC, Gastric Carcinoma, Pancreatic Adenocarcinoma, Colorectal Carcinoma, Neuroendocrine Tumors
- Interventions
- Lurbinectedin, Irinotecan
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 4
- States / cities
- Santa Monica, California • Boston, Massachusetts • Houston, Texas
- Conditions
- Recurrent Glioblastoma
- Interventions
- pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1), RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)
- Biological
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- hyperbaric oxygen, radiation therapy
- Drug · Radiation
- Lead sponsor
- Barrett Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Iponeurocytoma
- Interventions
- Dabrafenib, trametinib, Carboplatin, Vincristine
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Months to 17 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 10
- States / cities
- Orange, California • Washington D.C., District of Columbia • Miami, Florida + 7 more
- Conditions
- High Grade Glioma, Glioblastoma
- Interventions
- Standard Surgical Treatment, Intraoperative Electrocorticography
- Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Glioblastoma, Recurrent Glioblastoma
- Interventions
- Pembrolizumab, Olaparib, Temozolomide
- Drug
- Lead sponsor
- L. Nicolas Gonzalez Castro, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Glioblastoma Multiforme/Anaplastic Astrocytoma
- Interventions
- temozolomide, Hypofractionated radiation therapy, Intensity-modulated radiation therapy
- Drug · Radiation
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Brain Cancer, Glioblastoma Multiforme
- Interventions
- Vorinostat, Erlotinib, Temozolomide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
- Interventions
- Indoximod, Temozolomide, Bevacizumab, Stereotactic Radiation
- Drug · Radiation
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 17
- States / cities
- Castro Valley, California • Los Angeles, California • Orange, California + 14 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Bevacizumab, Tarceva, Temozolomide
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Glioblastoma, Surgery, High Grade Glioma
- Interventions
- Neoadjuvant chemoradiation, Drug Therapy with Temozolomide (benzolamide) (Standard of Care), Surgery post Radiation and Temozolomide (benzolamide)
- Radiation · Drug · Procedure
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
- Conditions
- Glioblastoma
- Interventions
- enzastaurin, lomustine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 39 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- AZD7451
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Gliosarcoma
- Interventions
- Adavosertib, Laboratory Biomarker Analysis, Pharmacological Study, Radiation Therapy
- Drug · Other · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 37 Months to 21 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, GBM
- Interventions
- pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td, Saline, pp65-flLAMP DC with GM-CSF
- Biological · Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Orlando, Florida • Durham, North Carolina